Review



anti-mouse cd8α pe-cy7  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Thermo Fisher anti-mouse cd8α pe-cy7
    rhIL-7-hyFc treatment increases PD-1 − bystander <t>CD8</t> TILs (A‒E) scRNA-seq analysis of CD8 TILs. Mice bearing palpable MC38 tumors treated subcutaneously (s.c.) with rhIL-7-hyFc (10 mg kg −1 ). Tumors were collected 7 days after rhIL-7-hyFc treatment. Collected tumor tissues were pooled for analysis ( n = 5–7 per group). Unless specified otherwise, the data include TILs from both buffer- and rhIL-7-hyFc-treated mice. (A) UMAP plots of six distinct CD8 TIL clusters from MC38-bearing mice, numbered and colored according to the transcriptional clusters. (B) Dot plot showing the expression of various T cell-related genes in the six different clusters. (C) UMAP plot of top five expanded clones. (D) UMAP showing the distribution of expression of Pdcd1 transcript. (E) UMAP showing CD8 TIL clusters from buffer- or rhIL-7-hyFc-treated mice (left) and bar graph depicting the proportion of six clusters in each treatment condition (right). (F and G) rhIL-7-hyFc (10 mg kg −1 ) were treated s.c. in mice bearing various palpable tumors. Tumors were collected 7 days after rhIL-7-hyFc treatment ( n = 5–11 per group). (F) Frequency of PD-1 − CD8 T cells among total CD8 TILs. (G) Number of PD-1 + CD8 T cells (left) and PD-1 − CD8 T cells (right). Numbers on the bar indicate fold changes between buffer- and rhIL-7-hyFc-treated groups. Data are shown as mean ± SEM and representative of two independent experiments. (H) Schematic of clinical study design. Patients with metastatic colorectal and ovarian cancer were treated with rhIL-7-hyFc. Pre- and post-treatment tumor samples were collected during the screening period and at indicated time points. (I) Percentage of total CD8 T cells (left), PD-1 + CD8 T cells (middle), and PD-1 − CD8 T cells (right) among the total cells. Each dot represents a single region of interest (ROI) in each patient’s sample. The ROIs were manually designated by pathologists. (J) Representative immunofluorescence images of tumor biopsies from patient SB13. Purple, CD8; yellow, PD-1; gray, DAPI. Magnification, ×200, scale bars, 50 μm ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired (F, G, and I) two-tailed Student’s t test. See also <xref ref-type=Figures S1 ; Table S1 . " width="250" height="auto" />
    Anti Mouse Cd8α Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8%CE%B1+pe-cy7/anti+cd4+fitc/pmc11148861-7-0-6
    Average 90 stars, based on 1 article reviews
    anti-mouse cd8α pe-cy7 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy"

    Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

    Journal: Cell Reports Medicine

    doi: 10.1016/j.xcrm.2024.101567

    rhIL-7-hyFc treatment increases PD-1 − bystander CD8 TILs (A‒E) scRNA-seq analysis of CD8 TILs. Mice bearing palpable MC38 tumors treated subcutaneously (s.c.) with rhIL-7-hyFc (10 mg kg −1 ). Tumors were collected 7 days after rhIL-7-hyFc treatment. Collected tumor tissues were pooled for analysis ( n = 5–7 per group). Unless specified otherwise, the data include TILs from both buffer- and rhIL-7-hyFc-treated mice. (A) UMAP plots of six distinct CD8 TIL clusters from MC38-bearing mice, numbered and colored according to the transcriptional clusters. (B) Dot plot showing the expression of various T cell-related genes in the six different clusters. (C) UMAP plot of top five expanded clones. (D) UMAP showing the distribution of expression of Pdcd1 transcript. (E) UMAP showing CD8 TIL clusters from buffer- or rhIL-7-hyFc-treated mice (left) and bar graph depicting the proportion of six clusters in each treatment condition (right). (F and G) rhIL-7-hyFc (10 mg kg −1 ) were treated s.c. in mice bearing various palpable tumors. Tumors were collected 7 days after rhIL-7-hyFc treatment ( n = 5–11 per group). (F) Frequency of PD-1 − CD8 T cells among total CD8 TILs. (G) Number of PD-1 + CD8 T cells (left) and PD-1 − CD8 T cells (right). Numbers on the bar indicate fold changes between buffer- and rhIL-7-hyFc-treated groups. Data are shown as mean ± SEM and representative of two independent experiments. (H) Schematic of clinical study design. Patients with metastatic colorectal and ovarian cancer were treated with rhIL-7-hyFc. Pre- and post-treatment tumor samples were collected during the screening period and at indicated time points. (I) Percentage of total CD8 T cells (left), PD-1 + CD8 T cells (middle), and PD-1 − CD8 T cells (right) among the total cells. Each dot represents a single region of interest (ROI) in each patient’s sample. The ROIs were manually designated by pathologists. (J) Representative immunofluorescence images of tumor biopsies from patient SB13. Purple, CD8; yellow, PD-1; gray, DAPI. Magnification, ×200, scale bars, 50 μm ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired (F, G, and I) two-tailed Student’s t test. See also <xref ref-type=Figures S1 ; Table S1 . " title="rhIL-7-hyFc treatment increases PD-1 − bystander CD8 TILs (A‒E) scRNA-seq analysis of CD8 TILs. Mice ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: rhIL-7-hyFc treatment increases PD-1 − bystander CD8 TILs (A‒E) scRNA-seq analysis of CD8 TILs. Mice bearing palpable MC38 tumors treated subcutaneously (s.c.) with rhIL-7-hyFc (10 mg kg −1 ). Tumors were collected 7 days after rhIL-7-hyFc treatment. Collected tumor tissues were pooled for analysis ( n = 5–7 per group). Unless specified otherwise, the data include TILs from both buffer- and rhIL-7-hyFc-treated mice. (A) UMAP plots of six distinct CD8 TIL clusters from MC38-bearing mice, numbered and colored according to the transcriptional clusters. (B) Dot plot showing the expression of various T cell-related genes in the six different clusters. (C) UMAP plot of top five expanded clones. (D) UMAP showing the distribution of expression of Pdcd1 transcript. (E) UMAP showing CD8 TIL clusters from buffer- or rhIL-7-hyFc-treated mice (left) and bar graph depicting the proportion of six clusters in each treatment condition (right). (F and G) rhIL-7-hyFc (10 mg kg −1 ) were treated s.c. in mice bearing various palpable tumors. Tumors were collected 7 days after rhIL-7-hyFc treatment ( n = 5–11 per group). (F) Frequency of PD-1 − CD8 T cells among total CD8 TILs. (G) Number of PD-1 + CD8 T cells (left) and PD-1 − CD8 T cells (right). Numbers on the bar indicate fold changes between buffer- and rhIL-7-hyFc-treated groups. Data are shown as mean ± SEM and representative of two independent experiments. (H) Schematic of clinical study design. Patients with metastatic colorectal and ovarian cancer were treated with rhIL-7-hyFc. Pre- and post-treatment tumor samples were collected during the screening period and at indicated time points. (I) Percentage of total CD8 T cells (left), PD-1 + CD8 T cells (middle), and PD-1 − CD8 T cells (right) among the total cells. Each dot represents a single region of interest (ROI) in each patient’s sample. The ROIs were manually designated by pathologists. (J) Representative immunofluorescence images of tumor biopsies from patient SB13. Purple, CD8; yellow, PD-1; gray, DAPI. Magnification, ×200, scale bars, 50 μm ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired (F, G, and I) two-tailed Student’s t test. See also Figures S1 ; Table S1 .

    Techniques Used: Expressing, Clone Assay, Immunofluorescence, Two Tailed Test

    rhIL-7-hyFc treatment changes the transcriptome profiles of tumor-reactive and bystander CD8 TILs (A) UMAP of scTCR-seq data colored according to the clone size of expanded CD8 TILs from mice bearing MC38 tumors between groups (left) and a bar graph showing the proportion of CD8 TILs with each clone size between groups (right). (B) Number of DEGs in tumor-reactive and bystander CD8 TILs from tumor-bearing mice with rhIL-7-hyFc treatment compared with buffer treatment. (C) Top 5 enriched GO terms for up- or downregulated genes in tumor-reactive cells by rhIL-7-hyFc treatment. (D) Violin plots with an expression of genes related to T cell exhaustion, function, and TFs in tumor-reactive cells. (E) GSEA analysis with the gene set of exhausted vs. naive CD8 T cells (GEO: GSE9650 ), top TFs correlated with the dysfunctional program (Li et al. ), glycolysis (MSigDB: hallmark), and IFN-alpha response (MSigDB: hallmark) in tumor-reactive CD8 TILs. (F) Top 5 enriched GO terms for up- or downregulated genes in bystander cells by rhIL-7-hyFc treatment. (G) Violin plots with expression of genes related to ribosomal proteins, CM T cell, and T cell regulation in bystander cells. (H) GSEA analysis with the gene set of memory vs. exhausted CD8 T cells (GEO: GSE9650 ), positive regulation of TCR pathway (GO: 0050862 ), oxidative phosphorylation (MSigDB: hallmark), and IFN-alpha response (MSigDB: hallmark) in bystander CD8 TILs. Tumor-reactive cells are defined as cells with a clone size of 3 or greater, and bystander cells are defined as cells with a clone size of 1 or 2 and belonging to one of clusters 0, 2, 3, and 5. BIR., break-induced replication; DSBs., double-strand breaks; neg., negative; reg., regulation; sys., system; Pos., positive. See also <xref ref-type=Figures S2 and ; Table S2 . " title="... changes the transcriptome profiles of tumor-reactive and bystander CD8 TILs (A) UMAP of scTCR-seq data colored according ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: rhIL-7-hyFc treatment changes the transcriptome profiles of tumor-reactive and bystander CD8 TILs (A) UMAP of scTCR-seq data colored according to the clone size of expanded CD8 TILs from mice bearing MC38 tumors between groups (left) and a bar graph showing the proportion of CD8 TILs with each clone size between groups (right). (B) Number of DEGs in tumor-reactive and bystander CD8 TILs from tumor-bearing mice with rhIL-7-hyFc treatment compared with buffer treatment. (C) Top 5 enriched GO terms for up- or downregulated genes in tumor-reactive cells by rhIL-7-hyFc treatment. (D) Violin plots with an expression of genes related to T cell exhaustion, function, and TFs in tumor-reactive cells. (E) GSEA analysis with the gene set of exhausted vs. naive CD8 T cells (GEO: GSE9650 ), top TFs correlated with the dysfunctional program (Li et al. ), glycolysis (MSigDB: hallmark), and IFN-alpha response (MSigDB: hallmark) in tumor-reactive CD8 TILs. (F) Top 5 enriched GO terms for up- or downregulated genes in bystander cells by rhIL-7-hyFc treatment. (G) Violin plots with expression of genes related to ribosomal proteins, CM T cell, and T cell regulation in bystander cells. (H) GSEA analysis with the gene set of memory vs. exhausted CD8 T cells (GEO: GSE9650 ), positive regulation of TCR pathway (GO: 0050862 ), oxidative phosphorylation (MSigDB: hallmark), and IFN-alpha response (MSigDB: hallmark) in bystander CD8 TILs. Tumor-reactive cells are defined as cells with a clone size of 3 or greater, and bystander cells are defined as cells with a clone size of 1 or 2 and belonging to one of clusters 0, 2, 3, and 5. BIR., break-induced replication; DSBs., double-strand breaks; neg., negative; reg., regulation; sys., system; Pos., positive. See also Figures S2 and ; Table S2 .

    Techniques Used: Expressing, Phospho-proteomics

    TCE stimulation elicits tumoricidal activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Schematic protein structure of PD-L1×CD3 TCE. This figure was created with BioRender.com . (B) The cytotoxicity of PD-L1 −/− splenocytes from naive PD-L1-deficient mice was evaluated. These splenocytes were co-cultured with CTV-labeled MC38 WT or MC38 ΔPD−L1 tumor cells in the presence of TCE at indicated concentrations for 48 h ( n = 3 per group). (C‒F) Functional assay of PD-L1×CD3 TCE on rhIL-7-hyFc-induced tumor-reactive and bystander CD8 TILs ( n = 3 per group). (C) Experimental scheme. (D) Expression of PD-1 and GzmB in PD-1 + or PD-1 − CD8 T cells co-cultured with MC38 in the presence of TCE at indicated concentration (left) and frequencies of PD-1 + GzmB + cells among CD8 T cells. Black and blue dots indicate PD-1 + and PD-1 − CD8 TILs before co-culture, respectively (right). (E) Frequencies of PD-1 + Prf + cells among CD8 T cells. (F) Cytotoxicity of PD-1 + and PD-1 − CD8 T cells in the presence of TCE. The expression of ghost dye in tumor cells was measured by flow cytometry. CTV + Ghost dye + cells are considered dead tumor cells. (G‒K) The functional changes and antitumor effects of rhIL-7-hyFc-expanded PD-1 − bystander CD8 T cells were investigated ( n = 5–7 per group). (G) Experimental scheme. MC38-bearing RAG1 −/− mice were injected i.t. with 4 × 10 6 CD8 + CD44 + CD62L + PD-1 − T cells sourced from the spleen and lymph nodes of C57BL/6 mice treated with rhIL-7-hyFc (10 mg kg −1 ). PD-L1×CD3 TCE (2 μg) or PBS was administered i.t. 5 times daily from the next day after T cell transfer. For flow cytometry analysis, tumors were collected 24 h after the second TCE treatment. (H) Average (left) and individual (right) tumor growth curves of MC38-bearing RAG1 −/− mice. The timing of TCE or PBS administration is indicated by blue or gray columns, respectively. (I) Representative plots showing the expression of GzmB in CD8 T cells (left) and frequency of GzmB + cells among CD8 T cells (right). (J) Representative plots showing the expression of Prf in CD8 T cells (left) and frequency of Prf + cells among CD8 T cells (right). (K) Representative plots showing the expression of Ki-67 in CD8 T cells (left) and frequency of Ki-67 + cells among CD8 T cells (right). Data are shown as mean ± SEM and representative of two or three independent experiments (B, D-F, and H) or a summary of two independent experiments (I–K). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired two-tailed Student’s t test (B, I, J, and K), by one-way ANOVA and Tukey’s multiple comparisons test (D–F), and by two-way ANOVA and Tukey’s multiple comparisons test (H). ns, not significant. See also <xref ref-type=Figures S3 and . " title="TCE stimulation elicits tumoricidal activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Schematic protein structure of PD-L1×CD3 TCE. ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: TCE stimulation elicits tumoricidal activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Schematic protein structure of PD-L1×CD3 TCE. This figure was created with BioRender.com . (B) The cytotoxicity of PD-L1 −/− splenocytes from naive PD-L1-deficient mice was evaluated. These splenocytes were co-cultured with CTV-labeled MC38 WT or MC38 ΔPD−L1 tumor cells in the presence of TCE at indicated concentrations for 48 h ( n = 3 per group). (C‒F) Functional assay of PD-L1×CD3 TCE on rhIL-7-hyFc-induced tumor-reactive and bystander CD8 TILs ( n = 3 per group). (C) Experimental scheme. (D) Expression of PD-1 and GzmB in PD-1 + or PD-1 − CD8 T cells co-cultured with MC38 in the presence of TCE at indicated concentration (left) and frequencies of PD-1 + GzmB + cells among CD8 T cells. Black and blue dots indicate PD-1 + and PD-1 − CD8 TILs before co-culture, respectively (right). (E) Frequencies of PD-1 + Prf + cells among CD8 T cells. (F) Cytotoxicity of PD-1 + and PD-1 − CD8 T cells in the presence of TCE. The expression of ghost dye in tumor cells was measured by flow cytometry. CTV + Ghost dye + cells are considered dead tumor cells. (G‒K) The functional changes and antitumor effects of rhIL-7-hyFc-expanded PD-1 − bystander CD8 T cells were investigated ( n = 5–7 per group). (G) Experimental scheme. MC38-bearing RAG1 −/− mice were injected i.t. with 4 × 10 6 CD8 + CD44 + CD62L + PD-1 − T cells sourced from the spleen and lymph nodes of C57BL/6 mice treated with rhIL-7-hyFc (10 mg kg −1 ). PD-L1×CD3 TCE (2 μg) or PBS was administered i.t. 5 times daily from the next day after T cell transfer. For flow cytometry analysis, tumors were collected 24 h after the second TCE treatment. (H) Average (left) and individual (right) tumor growth curves of MC38-bearing RAG1 −/− mice. The timing of TCE or PBS administration is indicated by blue or gray columns, respectively. (I) Representative plots showing the expression of GzmB in CD8 T cells (left) and frequency of GzmB + cells among CD8 T cells (right). (J) Representative plots showing the expression of Prf in CD8 T cells (left) and frequency of Prf + cells among CD8 T cells (right). (K) Representative plots showing the expression of Ki-67 in CD8 T cells (left) and frequency of Ki-67 + cells among CD8 T cells (right). Data are shown as mean ± SEM and representative of two or three independent experiments (B, D-F, and H) or a summary of two independent experiments (I–K). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired two-tailed Student’s t test (B, I, J, and K), by one-way ANOVA and Tukey’s multiple comparisons test (D–F), and by two-way ANOVA and Tukey’s multiple comparisons test (H). ns, not significant. See also Figures S3 and .

    Techniques Used: Activity Assay, Cell Culture, Labeling, Functional Assay, Expressing, Concentration Assay, Co-Culture Assay, Flow Cytometry, Injection, Two Tailed Test

    TCE combination promotes the cytotoxic activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Experimental scheme. Mice bearing palpable MC38 tumors were injected s.c. with rhIL-7-hyFc (1.25 mg kg −1 ). Three days after rhIL-7-hyFc treatment, mice were treated i.v. with PD-L1×CD3 TCE (0.4 μg) 2 times daily. Twenty-four hours after the last treatment, mice were analyzed for TILs ( n = 4–6 per group). (B) Frequencies (left) and numbers (right) of CD8 T, CD4 T reg , CD4 non-T reg , and NK cells. (C) Frequencies of PD-1 − cells (left) and numbers of PD-1 + and PD-1 − cells among the total CD8 T cells (right). (D) Representative plots showing the expression of CD44 and CD62L in PD-1 − CD8 T cells. (E) Frequencies of CD44 + CD62L + (left) and CD44 + CD62L − (right) cells among PD-1 − CD8 T cells. (F, H, and I) Frequencies (left) and numbers (right) of GzmB + cells (F), Prf + cells (H), and Ki-67 + cells (I) among PD-1 − CD8 T cells. (G) Histogram of GzmB expression in PD-1 − CD8 T cells (left) and fold change of GzmB geometric mean fluorescence intensity (gMFI) compared with the buffer group in PD-1 − CD8 T cells. Data are shown as mean ± SEM and summary of two independent experiments (B, C, F, G, and I) or representative of two independent experiments (E and H). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA and Tukey’s multiple comparisons test. ns, not significant. See also <xref ref-type=Figures S7 and . " title="... combination promotes the cytotoxic activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Experimental scheme. Mice bearing palpable MC38 ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: TCE combination promotes the cytotoxic activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Experimental scheme. Mice bearing palpable MC38 tumors were injected s.c. with rhIL-7-hyFc (1.25 mg kg −1 ). Three days after rhIL-7-hyFc treatment, mice were treated i.v. with PD-L1×CD3 TCE (0.4 μg) 2 times daily. Twenty-four hours after the last treatment, mice were analyzed for TILs ( n = 4–6 per group). (B) Frequencies (left) and numbers (right) of CD8 T, CD4 T reg , CD4 non-T reg , and NK cells. (C) Frequencies of PD-1 − cells (left) and numbers of PD-1 + and PD-1 − cells among the total CD8 T cells (right). (D) Representative plots showing the expression of CD44 and CD62L in PD-1 − CD8 T cells. (E) Frequencies of CD44 + CD62L + (left) and CD44 + CD62L − (right) cells among PD-1 − CD8 T cells. (F, H, and I) Frequencies (left) and numbers (right) of GzmB + cells (F), Prf + cells (H), and Ki-67 + cells (I) among PD-1 − CD8 T cells. (G) Histogram of GzmB expression in PD-1 − CD8 T cells (left) and fold change of GzmB geometric mean fluorescence intensity (gMFI) compared with the buffer group in PD-1 − CD8 T cells. Data are shown as mean ± SEM and summary of two independent experiments (B, C, F, G, and I) or representative of two independent experiments (E and H). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA and Tukey’s multiple comparisons test. ns, not significant. See also Figures S7 and .

    Techniques Used: Activity Assay, Injection, Expressing, Fluorescence

    Transcriptome analysis of CD8 TIL subsets in combination therapy scRNA-seq results of CD8 TILs from mice bearing MC38 tumors treated with rhIL-7-hyFc alone or a combination of rhIL-7-hyFc and TCE. C57BL/6 mice bearing palpable MC38 tumors were injected s.c. with rhIL-7-hyFc (1.25 mg kg −1 ). Three days after rhIL-7-hyFc treatment, mice were treated i.v. with PD-L1×CD3 TCE (0.4 μg) three times daily. Tumors were collected 24 h after the last treatment. Collected tumor tissues were pooled for analysis ( n = 12 rhIL-7-hyFc and n = 24 combination). (A) UMAP plot showing each CD8 TIL cluster. (B) Supervised clustering of CD8 TILs according to gene-expression characteristics (left) and bar graph depicting the proportion of three CD8 TIL subclusters in each treatment condition (right). (C) Heatmap showing the DEGs between supervised groups. (D) Featured plots showing the expression of Pdcd1 (left) and Tcf7 (right) genes. (E) UMAP plot of top six most expanded clones. (F) Number of DEGs in each supervised CD8 TIL subcluster from mice with combination therapy compared with the rhIL-7-hyFc-treated group. (G) Dot plots of GO enrichment analysis of upregulated DEGs by combination therapy in each CD8 TIL subcluster. (H) Violin plots showing the expression of genes related to exhaustion, CM-associated, cytotoxicity, T cell activation, glycolysis, and cell motility. See also <xref ref-type=Figures S9 and ; Table S3 . " title="Transcriptome analysis of CD8 TIL subsets in combination therapy scRNA-seq results of ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Transcriptome analysis of CD8 TIL subsets in combination therapy scRNA-seq results of CD8 TILs from mice bearing MC38 tumors treated with rhIL-7-hyFc alone or a combination of rhIL-7-hyFc and TCE. C57BL/6 mice bearing palpable MC38 tumors were injected s.c. with rhIL-7-hyFc (1.25 mg kg −1 ). Three days after rhIL-7-hyFc treatment, mice were treated i.v. with PD-L1×CD3 TCE (0.4 μg) three times daily. Tumors were collected 24 h after the last treatment. Collected tumor tissues were pooled for analysis ( n = 12 rhIL-7-hyFc and n = 24 combination). (A) UMAP plot showing each CD8 TIL cluster. (B) Supervised clustering of CD8 TILs according to gene-expression characteristics (left) and bar graph depicting the proportion of three CD8 TIL subclusters in each treatment condition (right). (C) Heatmap showing the DEGs between supervised groups. (D) Featured plots showing the expression of Pdcd1 (left) and Tcf7 (right) genes. (E) UMAP plot of top six most expanded clones. (F) Number of DEGs in each supervised CD8 TIL subcluster from mice with combination therapy compared with the rhIL-7-hyFc-treated group. (G) Dot plots of GO enrichment analysis of upregulated DEGs by combination therapy in each CD8 TIL subcluster. (H) Violin plots showing the expression of genes related to exhaustion, CM-associated, cytotoxicity, T cell activation, glycolysis, and cell motility. See also Figures S9 and ; Table S3 .

    Techniques Used: Injection, Gene Expression, Expressing, Clone Assay, Activation Assay


    Figure Legend Snippet:

    Techniques Used: Purification, Recombinant, Formulation, Flow Cytometry, Amplification, Software, Staining

    Related Articles

    Incubation:

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μs OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Article Title: Erythrocyte-binding therapeutics
    Article Snippet: Antibodies and Flow Cytometry The following anti-mouse antibodies were used for flow cytometry: CD1d Pacific Blue, CD3ε PerCP-Cy5.5, CD8α PE-Cy7, CD11b PE-Cy7, CD11c Pacific Blue, biotinylated CD45, CD45.2 Pacific Blue, CD45 Pacific Blue, IFNγ-APC, CD8α APC-eF780, CD44 PE-Cy5.5, CD62L PE, CD205 PE-Cy7, F4/80 PE, I-A/I-E MHCII FITC (all from eBioscience), in addition to fixable live/dead dye (Invitrogen), annexin-V-Cy5 labeling kit (BioVision), streptavidin Pacific Orange (Invitrogen), and anti-OVA-FITC (Abcam).

    Article Title: RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation
    Article Snippet: Antibodies to mouse antigens were as follows: CD24 FITC (clone M1/69, BD, 1:1000 dilution), CD69 PE (H1.2F3, BD, 1:100), TCRβ APC (H57-597, eBiosciences, 1:500), CD4 Alexa Fluor 700 (GK1.5, eBioscience, 1:1000), CD8α PE-Cy7 (53-6.7, eBioscience, 1:1000), CD44 PE-Cy5.5 (IM7, eBioscience, 1:500), CD25 PE-Cy7 (PC61.5, eBioscience, 1:500), and Thy1.2 FITC (CD90.2, clone 30-H12, BD, 1:500).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μg OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
    Article Snippet: Pooled DCs were washed in flow buffer (PBS with 0.5% FBS), incubated with anti-mouse Fc Block (Thermo Fisher Scientific), and then stained with CD8α PE-Cy7 (Thermo Fisher; clone: 53–6.7), and CD24 Pacific Blue (Biolegend; clone: M1/69).

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Blocking Assay:

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μs OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Article Title: Erythrocyte-binding therapeutics
    Article Snippet: Antibodies and Flow Cytometry The following anti-mouse antibodies were used for flow cytometry: CD1d Pacific Blue, CD3ε PerCP-Cy5.5, CD8α PE-Cy7, CD11b PE-Cy7, CD11c Pacific Blue, biotinylated CD45, CD45.2 Pacific Blue, CD45 Pacific Blue, IFNγ-APC, CD8α APC-eF780, CD44 PE-Cy5.5, CD62L PE, CD205 PE-Cy7, F4/80 PE, I-A/I-E MHCII FITC (all from eBioscience), in addition to fixable live/dead dye (Invitrogen), annexin-V-Cy5 labeling kit (BioVision), streptavidin Pacific Orange (Invitrogen), and anti-OVA-FITC (Abcam).

    Article Title: RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation
    Article Snippet: Antibodies to mouse antigens were as follows: CD24 FITC (clone M1/69, BD, 1:1000 dilution), CD69 PE (H1.2F3, BD, 1:100), TCRβ APC (H57-597, eBiosciences, 1:500), CD4 Alexa Fluor 700 (GK1.5, eBioscience, 1:1000), CD8α PE-Cy7 (53-6.7, eBioscience, 1:1000), CD44 PE-Cy5.5 (IM7, eBioscience, 1:500), CD25 PE-Cy7 (PC61.5, eBioscience, 1:500), and Thy1.2 FITC (CD90.2, clone 30-H12, BD, 1:500).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μg OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
    Article Snippet: Pooled DCs were washed in flow buffer (PBS with 0.5% FBS), incubated with anti-mouse Fc Block (Thermo Fisher Scientific), and then stained with CD8α PE-Cy7 (Thermo Fisher; clone: 53–6.7), and CD24 Pacific Blue (Biolegend; clone: M1/69).

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Staining:

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μs OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Article Title: Erythrocyte-binding therapeutics
    Article Snippet: Antibodies and Flow Cytometry The following anti-mouse antibodies were used for flow cytometry: CD1d Pacific Blue, CD3ε PerCP-Cy5.5, CD8α PE-Cy7, CD11b PE-Cy7, CD11c Pacific Blue, biotinylated CD45, CD45.2 Pacific Blue, CD45 Pacific Blue, IFNγ-APC, CD8α APC-eF780, CD44 PE-Cy5.5, CD62L PE, CD205 PE-Cy7, F4/80 PE, I-A/I-E MHCII FITC (all from eBioscience), in addition to fixable live/dead dye (Invitrogen), annexin-V-Cy5 labeling kit (BioVision), streptavidin Pacific Orange (Invitrogen), and anti-OVA-FITC (Abcam).

    Article Title: RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation
    Article Snippet: Antibodies to mouse antigens were as follows: CD24 FITC (clone M1/69, BD, 1:1000 dilution), CD69 PE (H1.2F3, BD, 1:100), TCRβ APC (H57-597, eBiosciences, 1:500), CD4 Alexa Fluor 700 (GK1.5, eBioscience, 1:1000), CD8α PE-Cy7 (53-6.7, eBioscience, 1:1000), CD44 PE-Cy5.5 (IM7, eBioscience, 1:500), CD25 PE-Cy7 (PC61.5, eBioscience, 1:500), and Thy1.2 FITC (CD90.2, clone 30-H12, BD, 1:500).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μg OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
    Article Snippet: Pooled DCs were washed in flow buffer (PBS with 0.5% FBS), incubated with anti-mouse Fc Block (Thermo Fisher Scientific), and then stained with CD8α PE-Cy7 (Thermo Fisher; clone: 53–6.7), and CD24 Pacific Blue (Biolegend; clone: M1/69).

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Cytometry:

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μs OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Article Title: Erythrocyte-binding therapeutics
    Article Snippet: Antibodies and Flow Cytometry The following anti-mouse antibodies were used for flow cytometry: CD1d Pacific Blue, CD3ε PerCP-Cy5.5, CD8α PE-Cy7, CD11b PE-Cy7, CD11c Pacific Blue, biotinylated CD45, CD45.2 Pacific Blue, CD45 Pacific Blue, IFNγ-APC, CD8α APC-eF780, CD44 PE-Cy5.5, CD62L PE, CD205 PE-Cy7, F4/80 PE, I-A/I-E MHCII FITC (all from eBioscience), in addition to fixable live/dead dye (Invitrogen), annexin-V-Cy5 labeling kit (BioVision), streptavidin Pacific Orange (Invitrogen), and anti-OVA-FITC (Abcam).

    Article Title: RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation
    Article Snippet: Antibodies to mouse antigens were as follows: CD24 FITC (clone M1/69, BD, 1:1000 dilution), CD69 PE (H1.2F3, BD, 1:100), TCRβ APC (H57-597, eBiosciences, 1:500), CD4 Alexa Fluor 700 (GK1.5, eBioscience, 1:1000), CD8α PE-Cy7 (53-6.7, eBioscience, 1:1000), CD44 PE-Cy5.5 (IM7, eBioscience, 1:500), CD25 PE-Cy7 (PC61.5, eBioscience, 1:500), and Thy1.2 FITC (CD90.2, clone 30-H12, BD, 1:500).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μg OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
    Article Snippet: Pooled DCs were washed in flow buffer (PBS with 0.5% FBS), incubated with anti-mouse Fc Block (Thermo Fisher Scientific), and then stained with CD8α PE-Cy7 (Thermo Fisher; clone: 53–6.7), and CD24 Pacific Blue (Biolegend; clone: M1/69).

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Isolation:

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μs OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Article Title: Erythrocyte-binding therapeutics
    Article Snippet: Antibodies and Flow Cytometry The following anti-mouse antibodies were used for flow cytometry: CD1d Pacific Blue, CD3ε PerCP-Cy5.5, CD8α PE-Cy7, CD11b PE-Cy7, CD11c Pacific Blue, biotinylated CD45, CD45.2 Pacific Blue, CD45 Pacific Blue, IFNγ-APC, CD8α APC-eF780, CD44 PE-Cy5.5, CD62L PE, CD205 PE-Cy7, F4/80 PE, I-A/I-E MHCII FITC (all from eBioscience), in addition to fixable live/dead dye (Invitrogen), annexin-V-Cy5 labeling kit (BioVision), streptavidin Pacific Orange (Invitrogen), and anti-OVA-FITC (Abcam).

    Article Title: RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation
    Article Snippet: Antibodies to mouse antigens were as follows: CD24 FITC (clone M1/69, BD, 1:1000 dilution), CD69 PE (H1.2F3, BD, 1:100), TCRβ APC (H57-597, eBiosciences, 1:500), CD4 Alexa Fluor 700 (GK1.5, eBioscience, 1:1000), CD8α PE-Cy7 (53-6.7, eBioscience, 1:1000), CD44 PE-Cy5.5 (IM7, eBioscience, 1:500), CD25 PE-Cy7 (PC61.5, eBioscience, 1:500), and Thy1.2 FITC (CD90.2, clone 30-H12, BD, 1:500).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μg OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
    Article Snippet: Pooled DCs were washed in flow buffer (PBS with 0.5% FBS), incubated with anti-mouse Fc Block (Thermo Fisher Scientific), and then stained with CD8α PE-Cy7 (Thermo Fisher; clone: 53–6.7), and CD24 Pacific Blue (Biolegend; clone: M1/69).

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Flow Cytometry:

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μs OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Article Title: Erythrocyte-binding therapeutics
    Article Snippet: Antibodies and Flow Cytometry The following anti-mouse antibodies were used for flow cytometry: CD1d Pacific Blue, CD3ε PerCP-Cy5.5, CD8α PE-Cy7, CD11b PE-Cy7, CD11c Pacific Blue, biotinylated CD45, CD45.2 Pacific Blue, CD45 Pacific Blue, IFNγ-APC, CD8α APC-eF780, CD44 PE-Cy5.5, CD62L PE, CD205 PE-Cy7, F4/80 PE, I-A/I-E MHCII FITC (all from eBioscience), in addition to fixable live/dead dye (Invitrogen), annexin-V-Cy5 labeling kit (BioVision), streptavidin Pacific Orange (Invitrogen), and anti-OVA-FITC (Abcam).

    Article Title: RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation
    Article Snippet: Antibodies to mouse antigens were as follows: CD24 FITC (clone M1/69, BD, 1:1000 dilution), CD69 PE (H1.2F3, BD, 1:100), TCRβ APC (H57-597, eBiosciences, 1:500), CD4 Alexa Fluor 700 (GK1.5, eBioscience, 1:1000), CD8α PE-Cy7 (53-6.7, eBioscience, 1:1000), CD44 PE-Cy5.5 (IM7, eBioscience, 1:500), CD25 PE-Cy7 (PC61.5, eBioscience, 1:500), and Thy1.2 FITC (CD90.2, clone 30-H12, BD, 1:500).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μg OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
    Article Snippet: Pooled DCs were washed in flow buffer (PBS with 0.5% FBS), incubated with anti-mouse Fc Block (Thermo Fisher Scientific), and then stained with CD8α PE-Cy7 (Thermo Fisher; clone: 53–6.7), and CD24 Pacific Blue (Biolegend; clone: M1/69).

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Expressing:

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μs OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Article Title: Erythrocyte-binding therapeutics
    Article Snippet: Antibodies and Flow Cytometry The following anti-mouse antibodies were used for flow cytometry: CD1d Pacific Blue, CD3ε PerCP-Cy5.5, CD8α PE-Cy7, CD11b PE-Cy7, CD11c Pacific Blue, biotinylated CD45, CD45.2 Pacific Blue, CD45 Pacific Blue, IFNγ-APC, CD8α APC-eF780, CD44 PE-Cy5.5, CD62L PE, CD205 PE-Cy7, F4/80 PE, I-A/I-E MHCII FITC (all from eBioscience), in addition to fixable live/dead dye (Invitrogen), annexin-V-Cy5 labeling kit (BioVision), streptavidin Pacific Orange (Invitrogen), and anti-OVA-FITC (Abcam).

    Article Title: RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation
    Article Snippet: Antibodies to mouse antigens were as follows: CD24 FITC (clone M1/69, BD, 1:1000 dilution), CD69 PE (H1.2F3, BD, 1:100), TCRβ APC (H57-597, eBiosciences, 1:500), CD4 Alexa Fluor 700 (GK1.5, eBioscience, 1:1000), CD8α PE-Cy7 (53-6.7, eBioscience, 1:1000), CD44 PE-Cy5.5 (IM7, eBioscience, 1:500), CD25 PE-Cy7 (PC61.5, eBioscience, 1:500), and Thy1.2 FITC (CD90.2, clone 30-H12, BD, 1:500).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μg OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
    Article Snippet: Pooled DCs were washed in flow buffer (PBS with 0.5% FBS), incubated with anti-mouse Fc Block (Thermo Fisher Scientific), and then stained with CD8α PE-Cy7 (Thermo Fisher; clone: 53–6.7), and CD24 Pacific Blue (Biolegend; clone: M1/69).

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Co-Culture Assay:

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μs OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Article Title: Erythrocyte-binding therapeutics
    Article Snippet: Antibodies and Flow Cytometry The following anti-mouse antibodies were used for flow cytometry: CD1d Pacific Blue, CD3ε PerCP-Cy5.5, CD8α PE-Cy7, CD11b PE-Cy7, CD11c Pacific Blue, biotinylated CD45, CD45.2 Pacific Blue, CD45 Pacific Blue, IFNγ-APC, CD8α APC-eF780, CD44 PE-Cy5.5, CD62L PE, CD205 PE-Cy7, F4/80 PE, I-A/I-E MHCII FITC (all from eBioscience), in addition to fixable live/dead dye (Invitrogen), annexin-V-Cy5 labeling kit (BioVision), streptavidin Pacific Orange (Invitrogen), and anti-OVA-FITC (Abcam).

    Article Title: RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation
    Article Snippet: Antibodies to mouse antigens were as follows: CD24 FITC (clone M1/69, BD, 1:1000 dilution), CD69 PE (H1.2F3, BD, 1:100), TCRβ APC (H57-597, eBiosciences, 1:500), CD4 Alexa Fluor 700 (GK1.5, eBioscience, 1:1000), CD8α PE-Cy7 (53-6.7, eBioscience, 1:1000), CD44 PE-Cy5.5 (IM7, eBioscience, 1:500), CD25 PE-Cy7 (PC61.5, eBioscience, 1:500), and Thy1.2 FITC (CD90.2, clone 30-H12, BD, 1:500).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μg OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
    Article Snippet: Pooled DCs were washed in flow buffer (PBS with 0.5% FBS), incubated with anti-mouse Fc Block (Thermo Fisher Scientific), and then stained with CD8α PE-Cy7 (Thermo Fisher; clone: 53–6.7), and CD24 Pacific Blue (Biolegend; clone: M1/69).

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    RNA Sequencing Assay:

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μs OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Article Title: Erythrocyte-binding therapeutics
    Article Snippet: Antibodies and Flow Cytometry The following anti-mouse antibodies were used for flow cytometry: CD1d Pacific Blue, CD3ε PerCP-Cy5.5, CD8α PE-Cy7, CD11b PE-Cy7, CD11c Pacific Blue, biotinylated CD45, CD45.2 Pacific Blue, CD45 Pacific Blue, IFNγ-APC, CD8α APC-eF780, CD44 PE-Cy5.5, CD62L PE, CD205 PE-Cy7, F4/80 PE, I-A/I-E MHCII FITC (all from eBioscience), in addition to fixable live/dead dye (Invitrogen), annexin-V-Cy5 labeling kit (BioVision), streptavidin Pacific Orange (Invitrogen), and anti-OVA-FITC (Abcam).

    Article Title: RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation
    Article Snippet: Antibodies to mouse antigens were as follows: CD24 FITC (clone M1/69, BD, 1:1000 dilution), CD69 PE (H1.2F3, BD, 1:100), TCRβ APC (H57-597, eBiosciences, 1:500), CD4 Alexa Fluor 700 (GK1.5, eBioscience, 1:1000), CD8α PE-Cy7 (53-6.7, eBioscience, 1:1000), CD44 PE-Cy5.5 (IM7, eBioscience, 1:500), CD25 PE-Cy7 (PC61.5, eBioscience, 1:500), and Thy1.2 FITC (CD90.2, clone 30-H12, BD, 1:500).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μg OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
    Article Snippet: Pooled DCs were washed in flow buffer (PBS with 0.5% FBS), incubated with anti-mouse Fc Block (Thermo Fisher Scientific), and then stained with CD8α PE-Cy7 (Thermo Fisher; clone: 53–6.7), and CD24 Pacific Blue (Biolegend; clone: M1/69).

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Software:

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μs OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Article Title: Erythrocyte-binding therapeutics
    Article Snippet: Antibodies and Flow Cytometry The following anti-mouse antibodies were used for flow cytometry: CD1d Pacific Blue, CD3ε PerCP-Cy5.5, CD8α PE-Cy7, CD11b PE-Cy7, CD11c Pacific Blue, biotinylated CD45, CD45.2 Pacific Blue, CD45 Pacific Blue, IFNγ-APC, CD8α APC-eF780, CD44 PE-Cy5.5, CD62L PE, CD205 PE-Cy7, F4/80 PE, I-A/I-E MHCII FITC (all from eBioscience), in addition to fixable live/dead dye (Invitrogen), annexin-V-Cy5 labeling kit (BioVision), streptavidin Pacific Orange (Invitrogen), and anti-OVA-FITC (Abcam).

    Article Title: RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation
    Article Snippet: Antibodies to mouse antigens were as follows: CD24 FITC (clone M1/69, BD, 1:1000 dilution), CD69 PE (H1.2F3, BD, 1:100), TCRβ APC (H57-597, eBiosciences, 1:500), CD4 Alexa Fluor 700 (GK1.5, eBioscience, 1:1000), CD8α PE-Cy7 (53-6.7, eBioscience, 1:1000), CD44 PE-Cy5.5 (IM7, eBioscience, 1:500), CD25 PE-Cy7 (PC61.5, eBioscience, 1:500), and Thy1.2 FITC (CD90.2, clone 30-H12, BD, 1:500).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μg OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
    Article Snippet: Pooled DCs were washed in flow buffer (PBS with 0.5% FBS), incubated with anti-mouse Fc Block (Thermo Fisher Scientific), and then stained with CD8α PE-Cy7 (Thermo Fisher; clone: 53–6.7), and CD24 Pacific Blue (Biolegend; clone: M1/69).

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Labeling:

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μs OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.

    Article Title: Erythrocyte-binding therapeutics
    Article Snippet: Antibodies and Flow Cytometry The following anti-mouse antibodies were used for flow cytometry: CD1d Pacific Blue, CD3ε PerCP-Cy5.5, CD8α PE-Cy7, CD11b PE-Cy7, CD11c Pacific Blue, biotinylated CD45, CD45.2 Pacific Blue, CD45 Pacific Blue, IFNγ-APC, CD8α APC-eF780, CD44 PE-Cy5.5, CD62L PE, CD205 PE-Cy7, F4/80 PE, I-A/I-E MHCII FITC (all from eBioscience), in addition to fixable live/dead dye (Invitrogen), annexin-V-Cy5 labeling kit (BioVision), streptavidin Pacific Orange (Invitrogen), and anti-OVA-FITC (Abcam).

    Article Title: RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation
    Article Snippet: Antibodies to mouse antigens were as follows: CD24 FITC (clone M1/69, BD, 1:1000 dilution), CD69 PE (H1.2F3, BD, 1:100), TCRβ APC (H57-597, eBiosciences, 1:500), CD4 Alexa Fluor 700 (GK1.5, eBioscience, 1:1000), CD8α PE-Cy7 (53-6.7, eBioscience, 1:1000), CD44 PE-Cy5.5 (IM7, eBioscience, 1:500), CD25 PE-Cy7 (PC61.5, eBioscience, 1:500), and Thy1.2 FITC (CD90.2, clone 30-H12, BD, 1:500).

    Article Title: Antigen-specific tolerance and compositions for induction of same
    Article Snippet: 15 d following adoptive transfer, mice were challenged with 5 μg OVA and 25 ng ultra-pure Escherichia coli LPS (InvivoGen) in 25 μL intradermally into each front leg pad (total dose of 10 μg OVA and 50 ng LPS).

    Article Title: Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
    Article Snippet: Pooled DCs were washed in flow buffer (PBS with 0.5% FBS), incubated with anti-mouse Fc Block (Thermo Fisher Scientific), and then stained with CD8α PE-Cy7 (Thermo Fisher; clone: 53–6.7), and CD24 Pacific Blue (Biolegend; clone: M1/69).

    Article Title: Compositions for inducing antigen-specific tolerance
    Article Snippet: For flow cytometry analysis of intracellular cytokines, cells were restimulated in the presence of 1 mg/mL OVA or 1 μg/mL SIINFEKL peptide (Genscript) for 3 h. Brefeldin-A (Sigma, 5 μg/mL) was added and restimulation resumed for an additional 3 h prior to staining and flow cytometry analysis.



    Similar Products

    94
    Multi Sciences (Lianke) Biotech Co Ltd pe cy7 anti mouse cd8α
    Pe Cy7 Anti Mouse Cd8α, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8%CE%B1+pe-cy7/Anti-Mouse+CD8%CE%B1/10__1016_slash_j__celbio__2025__100182-452-21-24
    Average 94 stars, based on 1 article reviews
    pe cy7 anti mouse cd8α - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    Cytek Biosciences cd8α pe cy7
    Cd8α Pe Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8%CE%B1+pe-cy7/PE-Cyanine7+Anti-Mouse+CD8a/pmc12254332-26-0-4
    Average 93 stars, based on 1 article reviews
    cd8α pe cy7 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    88
    SouthernBiotech rat anti mouse cd8α pe cy7
    Rat Anti Mouse Cd8α Pe Cy7, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8%CE%B1+pe-cy7/Rat+Anti-Mouse+IgD-Alexa+Fluor+647/pm39674474-125-17-21
    Average 88 stars, based on 1 article reviews
    rat anti mouse cd8α pe cy7 - by Bioz Stars, 2026-09
    88/100 stars
      Buy from Supplier

    90
    Thermo Fisher anti-mouse cd8α pe-cy7
    rhIL-7-hyFc treatment increases PD-1 − bystander <t>CD8</t> TILs (A‒E) scRNA-seq analysis of CD8 TILs. Mice bearing palpable MC38 tumors treated subcutaneously (s.c.) with rhIL-7-hyFc (10 mg kg −1 ). Tumors were collected 7 days after rhIL-7-hyFc treatment. Collected tumor tissues were pooled for analysis ( n = 5–7 per group). Unless specified otherwise, the data include TILs from both buffer- and rhIL-7-hyFc-treated mice. (A) UMAP plots of six distinct CD8 TIL clusters from MC38-bearing mice, numbered and colored according to the transcriptional clusters. (B) Dot plot showing the expression of various T cell-related genes in the six different clusters. (C) UMAP plot of top five expanded clones. (D) UMAP showing the distribution of expression of Pdcd1 transcript. (E) UMAP showing CD8 TIL clusters from buffer- or rhIL-7-hyFc-treated mice (left) and bar graph depicting the proportion of six clusters in each treatment condition (right). (F and G) rhIL-7-hyFc (10 mg kg −1 ) were treated s.c. in mice bearing various palpable tumors. Tumors were collected 7 days after rhIL-7-hyFc treatment ( n = 5–11 per group). (F) Frequency of PD-1 − CD8 T cells among total CD8 TILs. (G) Number of PD-1 + CD8 T cells (left) and PD-1 − CD8 T cells (right). Numbers on the bar indicate fold changes between buffer- and rhIL-7-hyFc-treated groups. Data are shown as mean ± SEM and representative of two independent experiments. (H) Schematic of clinical study design. Patients with metastatic colorectal and ovarian cancer were treated with rhIL-7-hyFc. Pre- and post-treatment tumor samples were collected during the screening period and at indicated time points. (I) Percentage of total CD8 T cells (left), PD-1 + CD8 T cells (middle), and PD-1 − CD8 T cells (right) among the total cells. Each dot represents a single region of interest (ROI) in each patient’s sample. The ROIs were manually designated by pathologists. (J) Representative immunofluorescence images of tumor biopsies from patient SB13. Purple, CD8; yellow, PD-1; gray, DAPI. Magnification, ×200, scale bars, 50 μm ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired (F, G, and I) two-tailed Student’s t test. See also <xref ref-type=Figures S1 ; Table S1 . " width="250" height="auto" />
    Anti Mouse Cd8α Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8%CE%B1+pe-cy7/anti+cd4+fitc/pmc11148861-7-0-6
    Average 90 stars, based on 1 article reviews
    anti-mouse cd8α pe-cy7 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Cytek Biosciences cd8α-pe-cy7
    rhIL-7-hyFc treatment increases PD-1 − bystander <t>CD8</t> TILs (A‒E) scRNA-seq analysis of CD8 TILs. Mice bearing palpable MC38 tumors treated subcutaneously (s.c.) with rhIL-7-hyFc (10 mg kg −1 ). Tumors were collected 7 days after rhIL-7-hyFc treatment. Collected tumor tissues were pooled for analysis ( n = 5–7 per group). Unless specified otherwise, the data include TILs from both buffer- and rhIL-7-hyFc-treated mice. (A) UMAP plots of six distinct CD8 TIL clusters from MC38-bearing mice, numbered and colored according to the transcriptional clusters. (B) Dot plot showing the expression of various T cell-related genes in the six different clusters. (C) UMAP plot of top five expanded clones. (D) UMAP showing the distribution of expression of Pdcd1 transcript. (E) UMAP showing CD8 TIL clusters from buffer- or rhIL-7-hyFc-treated mice (left) and bar graph depicting the proportion of six clusters in each treatment condition (right). (F and G) rhIL-7-hyFc (10 mg kg −1 ) were treated s.c. in mice bearing various palpable tumors. Tumors were collected 7 days after rhIL-7-hyFc treatment ( n = 5–11 per group). (F) Frequency of PD-1 − CD8 T cells among total CD8 TILs. (G) Number of PD-1 + CD8 T cells (left) and PD-1 − CD8 T cells (right). Numbers on the bar indicate fold changes between buffer- and rhIL-7-hyFc-treated groups. Data are shown as mean ± SEM and representative of two independent experiments. (H) Schematic of clinical study design. Patients with metastatic colorectal and ovarian cancer were treated with rhIL-7-hyFc. Pre- and post-treatment tumor samples were collected during the screening period and at indicated time points. (I) Percentage of total CD8 T cells (left), PD-1 + CD8 T cells (middle), and PD-1 − CD8 T cells (right) among the total cells. Each dot represents a single region of interest (ROI) in each patient’s sample. The ROIs were manually designated by pathologists. (J) Representative immunofluorescence images of tumor biopsies from patient SB13. Purple, CD8; yellow, PD-1; gray, DAPI. Magnification, ×200, scale bars, 50 μm ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired (F, G, and I) two-tailed Student’s t test. See also <xref ref-type=Figures S1 ; Table S1 . " width="250" height="auto" />
    Cd8α Pe Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8%CE%B1+pe-cy7/cd8%CE%B1+antibody/bio_rxiv__2023__12__07__570707-364-75-78
    Average 90 stars, based on 1 article reviews
    cd8α-pe-cy7 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher anti-human cd8α–pe-cy7 (clone 53-6.7)
    rhIL-7-hyFc treatment increases PD-1 − bystander <t>CD8</t> TILs (A‒E) scRNA-seq analysis of CD8 TILs. Mice bearing palpable MC38 tumors treated subcutaneously (s.c.) with rhIL-7-hyFc (10 mg kg −1 ). Tumors were collected 7 days after rhIL-7-hyFc treatment. Collected tumor tissues were pooled for analysis ( n = 5–7 per group). Unless specified otherwise, the data include TILs from both buffer- and rhIL-7-hyFc-treated mice. (A) UMAP plots of six distinct CD8 TIL clusters from MC38-bearing mice, numbered and colored according to the transcriptional clusters. (B) Dot plot showing the expression of various T cell-related genes in the six different clusters. (C) UMAP plot of top five expanded clones. (D) UMAP showing the distribution of expression of Pdcd1 transcript. (E) UMAP showing CD8 TIL clusters from buffer- or rhIL-7-hyFc-treated mice (left) and bar graph depicting the proportion of six clusters in each treatment condition (right). (F and G) rhIL-7-hyFc (10 mg kg −1 ) were treated s.c. in mice bearing various palpable tumors. Tumors were collected 7 days after rhIL-7-hyFc treatment ( n = 5–11 per group). (F) Frequency of PD-1 − CD8 T cells among total CD8 TILs. (G) Number of PD-1 + CD8 T cells (left) and PD-1 − CD8 T cells (right). Numbers on the bar indicate fold changes between buffer- and rhIL-7-hyFc-treated groups. Data are shown as mean ± SEM and representative of two independent experiments. (H) Schematic of clinical study design. Patients with metastatic colorectal and ovarian cancer were treated with rhIL-7-hyFc. Pre- and post-treatment tumor samples were collected during the screening period and at indicated time points. (I) Percentage of total CD8 T cells (left), PD-1 + CD8 T cells (middle), and PD-1 − CD8 T cells (right) among the total cells. Each dot represents a single region of interest (ROI) in each patient’s sample. The ROIs were manually designated by pathologists. (J) Representative immunofluorescence images of tumor biopsies from patient SB13. Purple, CD8; yellow, PD-1; gray, DAPI. Magnification, ×200, scale bars, 50 μm ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired (F, G, and I) two-tailed Student’s t test. See also <xref ref-type=Figures S1 ; Table S1 . " width="250" height="auto" />
    Anti Human Cd8α–Pe Cy7 (Clone 53 6.7), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8%CE%B1+pe-cy7/cd8a+antibody/pm37390984-179-31-35
    Average 90 stars, based on 1 article reviews
    anti-human cd8α–pe-cy7 (clone 53-6.7) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher pe-cy7-anti-cd8α (53-6.7)
    rhIL-7-hyFc treatment increases PD-1 − bystander <t>CD8</t> TILs (A‒E) scRNA-seq analysis of CD8 TILs. Mice bearing palpable MC38 tumors treated subcutaneously (s.c.) with rhIL-7-hyFc (10 mg kg −1 ). Tumors were collected 7 days after rhIL-7-hyFc treatment. Collected tumor tissues were pooled for analysis ( n = 5–7 per group). Unless specified otherwise, the data include TILs from both buffer- and rhIL-7-hyFc-treated mice. (A) UMAP plots of six distinct CD8 TIL clusters from MC38-bearing mice, numbered and colored according to the transcriptional clusters. (B) Dot plot showing the expression of various T cell-related genes in the six different clusters. (C) UMAP plot of top five expanded clones. (D) UMAP showing the distribution of expression of Pdcd1 transcript. (E) UMAP showing CD8 TIL clusters from buffer- or rhIL-7-hyFc-treated mice (left) and bar graph depicting the proportion of six clusters in each treatment condition (right). (F and G) rhIL-7-hyFc (10 mg kg −1 ) were treated s.c. in mice bearing various palpable tumors. Tumors were collected 7 days after rhIL-7-hyFc treatment ( n = 5–11 per group). (F) Frequency of PD-1 − CD8 T cells among total CD8 TILs. (G) Number of PD-1 + CD8 T cells (left) and PD-1 − CD8 T cells (right). Numbers on the bar indicate fold changes between buffer- and rhIL-7-hyFc-treated groups. Data are shown as mean ± SEM and representative of two independent experiments. (H) Schematic of clinical study design. Patients with metastatic colorectal and ovarian cancer were treated with rhIL-7-hyFc. Pre- and post-treatment tumor samples were collected during the screening period and at indicated time points. (I) Percentage of total CD8 T cells (left), PD-1 + CD8 T cells (middle), and PD-1 − CD8 T cells (right) among the total cells. Each dot represents a single region of interest (ROI) in each patient’s sample. The ROIs were manually designated by pathologists. (J) Representative immunofluorescence images of tumor biopsies from patient SB13. Purple, CD8; yellow, PD-1; gray, DAPI. Magnification, ×200, scale bars, 50 μm ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired (F, G, and I) two-tailed Student’s t test. See also <xref ref-type=Figures S1 ; Table S1 . " width="250" height="auto" />
    Pe Cy7 Anti Cd8α (53 6.7), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8%CE%B1+pe-cy7/anti+cd4+fitc/pm36521002-29-45-61
    Average 90 stars, based on 1 article reviews
    pe-cy7-anti-cd8α (53-6.7) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    86
    Thermo Fisher cd8α pe cy7

    Cd8α Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8%CE%B1+pe-cy7/pmc09812409-351-53-17
    Average 86 stars, based on 1 article reviews
    cd8α pe cy7 - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    Image Search Results


    rhIL-7-hyFc treatment increases PD-1 − bystander CD8 TILs (A‒E) scRNA-seq analysis of CD8 TILs. Mice bearing palpable MC38 tumors treated subcutaneously (s.c.) with rhIL-7-hyFc (10 mg kg −1 ). Tumors were collected 7 days after rhIL-7-hyFc treatment. Collected tumor tissues were pooled for analysis ( n = 5–7 per group). Unless specified otherwise, the data include TILs from both buffer- and rhIL-7-hyFc-treated mice. (A) UMAP plots of six distinct CD8 TIL clusters from MC38-bearing mice, numbered and colored according to the transcriptional clusters. (B) Dot plot showing the expression of various T cell-related genes in the six different clusters. (C) UMAP plot of top five expanded clones. (D) UMAP showing the distribution of expression of Pdcd1 transcript. (E) UMAP showing CD8 TIL clusters from buffer- or rhIL-7-hyFc-treated mice (left) and bar graph depicting the proportion of six clusters in each treatment condition (right). (F and G) rhIL-7-hyFc (10 mg kg −1 ) were treated s.c. in mice bearing various palpable tumors. Tumors were collected 7 days after rhIL-7-hyFc treatment ( n = 5–11 per group). (F) Frequency of PD-1 − CD8 T cells among total CD8 TILs. (G) Number of PD-1 + CD8 T cells (left) and PD-1 − CD8 T cells (right). Numbers on the bar indicate fold changes between buffer- and rhIL-7-hyFc-treated groups. Data are shown as mean ± SEM and representative of two independent experiments. (H) Schematic of clinical study design. Patients with metastatic colorectal and ovarian cancer were treated with rhIL-7-hyFc. Pre- and post-treatment tumor samples were collected during the screening period and at indicated time points. (I) Percentage of total CD8 T cells (left), PD-1 + CD8 T cells (middle), and PD-1 − CD8 T cells (right) among the total cells. Each dot represents a single region of interest (ROI) in each patient’s sample. The ROIs were manually designated by pathologists. (J) Representative immunofluorescence images of tumor biopsies from patient SB13. Purple, CD8; yellow, PD-1; gray, DAPI. Magnification, ×200, scale bars, 50 μm ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired (F, G, and I) two-tailed Student’s t test. See also <xref ref-type=Figures S1 ; Table S1 . " width="100%" height="100%">

    Journal: Cell Reports Medicine

    Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

    doi: 10.1016/j.xcrm.2024.101567

    Figure Lengend Snippet: rhIL-7-hyFc treatment increases PD-1 − bystander CD8 TILs (A‒E) scRNA-seq analysis of CD8 TILs. Mice bearing palpable MC38 tumors treated subcutaneously (s.c.) with rhIL-7-hyFc (10 mg kg −1 ). Tumors were collected 7 days after rhIL-7-hyFc treatment. Collected tumor tissues were pooled for analysis ( n = 5–7 per group). Unless specified otherwise, the data include TILs from both buffer- and rhIL-7-hyFc-treated mice. (A) UMAP plots of six distinct CD8 TIL clusters from MC38-bearing mice, numbered and colored according to the transcriptional clusters. (B) Dot plot showing the expression of various T cell-related genes in the six different clusters. (C) UMAP plot of top five expanded clones. (D) UMAP showing the distribution of expression of Pdcd1 transcript. (E) UMAP showing CD8 TIL clusters from buffer- or rhIL-7-hyFc-treated mice (left) and bar graph depicting the proportion of six clusters in each treatment condition (right). (F and G) rhIL-7-hyFc (10 mg kg −1 ) were treated s.c. in mice bearing various palpable tumors. Tumors were collected 7 days after rhIL-7-hyFc treatment ( n = 5–11 per group). (F) Frequency of PD-1 − CD8 T cells among total CD8 TILs. (G) Number of PD-1 + CD8 T cells (left) and PD-1 − CD8 T cells (right). Numbers on the bar indicate fold changes between buffer- and rhIL-7-hyFc-treated groups. Data are shown as mean ± SEM and representative of two independent experiments. (H) Schematic of clinical study design. Patients with metastatic colorectal and ovarian cancer were treated with rhIL-7-hyFc. Pre- and post-treatment tumor samples were collected during the screening period and at indicated time points. (I) Percentage of total CD8 T cells (left), PD-1 + CD8 T cells (middle), and PD-1 − CD8 T cells (right) among the total cells. Each dot represents a single region of interest (ROI) in each patient’s sample. The ROIs were manually designated by pathologists. (J) Representative immunofluorescence images of tumor biopsies from patient SB13. Purple, CD8; yellow, PD-1; gray, DAPI. Magnification, ×200, scale bars, 50 μm ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired (F, G, and I) two-tailed Student’s t test. See also Figures S1 ; Table S1 .

    Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

    Techniques: Expressing, Clone Assay, Immunofluorescence, Two Tailed Test

    rhIL-7-hyFc treatment changes the transcriptome profiles of tumor-reactive and bystander CD8 TILs (A) UMAP of scTCR-seq data colored according to the clone size of expanded CD8 TILs from mice bearing MC38 tumors between groups (left) and a bar graph showing the proportion of CD8 TILs with each clone size between groups (right). (B) Number of DEGs in tumor-reactive and bystander CD8 TILs from tumor-bearing mice with rhIL-7-hyFc treatment compared with buffer treatment. (C) Top 5 enriched GO terms for up- or downregulated genes in tumor-reactive cells by rhIL-7-hyFc treatment. (D) Violin plots with an expression of genes related to T cell exhaustion, function, and TFs in tumor-reactive cells. (E) GSEA analysis with the gene set of exhausted vs. naive CD8 T cells (GEO: GSE9650 ), top TFs correlated with the dysfunctional program (Li et al. ), glycolysis (MSigDB: hallmark), and IFN-alpha response (MSigDB: hallmark) in tumor-reactive CD8 TILs. (F) Top 5 enriched GO terms for up- or downregulated genes in bystander cells by rhIL-7-hyFc treatment. (G) Violin plots with expression of genes related to ribosomal proteins, CM T cell, and T cell regulation in bystander cells. (H) GSEA analysis with the gene set of memory vs. exhausted CD8 T cells (GEO: GSE9650 ), positive regulation of TCR pathway (GO: 0050862 ), oxidative phosphorylation (MSigDB: hallmark), and IFN-alpha response (MSigDB: hallmark) in bystander CD8 TILs. Tumor-reactive cells are defined as cells with a clone size of 3 or greater, and bystander cells are defined as cells with a clone size of 1 or 2 and belonging to one of clusters 0, 2, 3, and 5. BIR., break-induced replication; DSBs., double-strand breaks; neg., negative; reg., regulation; sys., system; Pos., positive. See also <xref ref-type=Figures S2 and ; Table S2 . " width="100%" height="100%">

    Journal: Cell Reports Medicine

    Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

    doi: 10.1016/j.xcrm.2024.101567

    Figure Lengend Snippet: rhIL-7-hyFc treatment changes the transcriptome profiles of tumor-reactive and bystander CD8 TILs (A) UMAP of scTCR-seq data colored according to the clone size of expanded CD8 TILs from mice bearing MC38 tumors between groups (left) and a bar graph showing the proportion of CD8 TILs with each clone size between groups (right). (B) Number of DEGs in tumor-reactive and bystander CD8 TILs from tumor-bearing mice with rhIL-7-hyFc treatment compared with buffer treatment. (C) Top 5 enriched GO terms for up- or downregulated genes in tumor-reactive cells by rhIL-7-hyFc treatment. (D) Violin plots with an expression of genes related to T cell exhaustion, function, and TFs in tumor-reactive cells. (E) GSEA analysis with the gene set of exhausted vs. naive CD8 T cells (GEO: GSE9650 ), top TFs correlated with the dysfunctional program (Li et al. ), glycolysis (MSigDB: hallmark), and IFN-alpha response (MSigDB: hallmark) in tumor-reactive CD8 TILs. (F) Top 5 enriched GO terms for up- or downregulated genes in bystander cells by rhIL-7-hyFc treatment. (G) Violin plots with expression of genes related to ribosomal proteins, CM T cell, and T cell regulation in bystander cells. (H) GSEA analysis with the gene set of memory vs. exhausted CD8 T cells (GEO: GSE9650 ), positive regulation of TCR pathway (GO: 0050862 ), oxidative phosphorylation (MSigDB: hallmark), and IFN-alpha response (MSigDB: hallmark) in bystander CD8 TILs. Tumor-reactive cells are defined as cells with a clone size of 3 or greater, and bystander cells are defined as cells with a clone size of 1 or 2 and belonging to one of clusters 0, 2, 3, and 5. BIR., break-induced replication; DSBs., double-strand breaks; neg., negative; reg., regulation; sys., system; Pos., positive. See also Figures S2 and ; Table S2 .

    Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

    Techniques: Expressing, Phospho-proteomics

    TCE stimulation elicits tumoricidal activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Schematic protein structure of PD-L1×CD3 TCE. This figure was created with BioRender.com . (B) The cytotoxicity of PD-L1 −/− splenocytes from naive PD-L1-deficient mice was evaluated. These splenocytes were co-cultured with CTV-labeled MC38 WT or MC38 ΔPD−L1 tumor cells in the presence of TCE at indicated concentrations for 48 h ( n = 3 per group). (C‒F) Functional assay of PD-L1×CD3 TCE on rhIL-7-hyFc-induced tumor-reactive and bystander CD8 TILs ( n = 3 per group). (C) Experimental scheme. (D) Expression of PD-1 and GzmB in PD-1 + or PD-1 − CD8 T cells co-cultured with MC38 in the presence of TCE at indicated concentration (left) and frequencies of PD-1 + GzmB + cells among CD8 T cells. Black and blue dots indicate PD-1 + and PD-1 − CD8 TILs before co-culture, respectively (right). (E) Frequencies of PD-1 + Prf + cells among CD8 T cells. (F) Cytotoxicity of PD-1 + and PD-1 − CD8 T cells in the presence of TCE. The expression of ghost dye in tumor cells was measured by flow cytometry. CTV + Ghost dye + cells are considered dead tumor cells. (G‒K) The functional changes and antitumor effects of rhIL-7-hyFc-expanded PD-1 − bystander CD8 T cells were investigated ( n = 5–7 per group). (G) Experimental scheme. MC38-bearing RAG1 −/− mice were injected i.t. with 4 × 10 6 CD8 + CD44 + CD62L + PD-1 − T cells sourced from the spleen and lymph nodes of C57BL/6 mice treated with rhIL-7-hyFc (10 mg kg −1 ). PD-L1×CD3 TCE (2 μg) or PBS was administered i.t. 5 times daily from the next day after T cell transfer. For flow cytometry analysis, tumors were collected 24 h after the second TCE treatment. (H) Average (left) and individual (right) tumor growth curves of MC38-bearing RAG1 −/− mice. The timing of TCE or PBS administration is indicated by blue or gray columns, respectively. (I) Representative plots showing the expression of GzmB in CD8 T cells (left) and frequency of GzmB + cells among CD8 T cells (right). (J) Representative plots showing the expression of Prf in CD8 T cells (left) and frequency of Prf + cells among CD8 T cells (right). (K) Representative plots showing the expression of Ki-67 in CD8 T cells (left) and frequency of Ki-67 + cells among CD8 T cells (right). Data are shown as mean ± SEM and representative of two or three independent experiments (B, D-F, and H) or a summary of two independent experiments (I–K). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired two-tailed Student’s t test (B, I, J, and K), by one-way ANOVA and Tukey’s multiple comparisons test (D–F), and by two-way ANOVA and Tukey’s multiple comparisons test (H). ns, not significant. See also <xref ref-type=Figures S3 and . " width="100%" height="100%">

    Journal: Cell Reports Medicine

    Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

    doi: 10.1016/j.xcrm.2024.101567

    Figure Lengend Snippet: TCE stimulation elicits tumoricidal activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Schematic protein structure of PD-L1×CD3 TCE. This figure was created with BioRender.com . (B) The cytotoxicity of PD-L1 −/− splenocytes from naive PD-L1-deficient mice was evaluated. These splenocytes were co-cultured with CTV-labeled MC38 WT or MC38 ΔPD−L1 tumor cells in the presence of TCE at indicated concentrations for 48 h ( n = 3 per group). (C‒F) Functional assay of PD-L1×CD3 TCE on rhIL-7-hyFc-induced tumor-reactive and bystander CD8 TILs ( n = 3 per group). (C) Experimental scheme. (D) Expression of PD-1 and GzmB in PD-1 + or PD-1 − CD8 T cells co-cultured with MC38 in the presence of TCE at indicated concentration (left) and frequencies of PD-1 + GzmB + cells among CD8 T cells. Black and blue dots indicate PD-1 + and PD-1 − CD8 TILs before co-culture, respectively (right). (E) Frequencies of PD-1 + Prf + cells among CD8 T cells. (F) Cytotoxicity of PD-1 + and PD-1 − CD8 T cells in the presence of TCE. The expression of ghost dye in tumor cells was measured by flow cytometry. CTV + Ghost dye + cells are considered dead tumor cells. (G‒K) The functional changes and antitumor effects of rhIL-7-hyFc-expanded PD-1 − bystander CD8 T cells were investigated ( n = 5–7 per group). (G) Experimental scheme. MC38-bearing RAG1 −/− mice were injected i.t. with 4 × 10 6 CD8 + CD44 + CD62L + PD-1 − T cells sourced from the spleen and lymph nodes of C57BL/6 mice treated with rhIL-7-hyFc (10 mg kg −1 ). PD-L1×CD3 TCE (2 μg) or PBS was administered i.t. 5 times daily from the next day after T cell transfer. For flow cytometry analysis, tumors were collected 24 h after the second TCE treatment. (H) Average (left) and individual (right) tumor growth curves of MC38-bearing RAG1 −/− mice. The timing of TCE or PBS administration is indicated by blue or gray columns, respectively. (I) Representative plots showing the expression of GzmB in CD8 T cells (left) and frequency of GzmB + cells among CD8 T cells (right). (J) Representative plots showing the expression of Prf in CD8 T cells (left) and frequency of Prf + cells among CD8 T cells (right). (K) Representative plots showing the expression of Ki-67 in CD8 T cells (left) and frequency of Ki-67 + cells among CD8 T cells (right). Data are shown as mean ± SEM and representative of two or three independent experiments (B, D-F, and H) or a summary of two independent experiments (I–K). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired two-tailed Student’s t test (B, I, J, and K), by one-way ANOVA and Tukey’s multiple comparisons test (D–F), and by two-way ANOVA and Tukey’s multiple comparisons test (H). ns, not significant. See also Figures S3 and .

    Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

    Techniques: Activity Assay, Cell Culture, Labeling, Functional Assay, Expressing, Concentration Assay, Co-Culture Assay, Flow Cytometry, Injection, Two Tailed Test

    TCE combination promotes the cytotoxic activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Experimental scheme. Mice bearing palpable MC38 tumors were injected s.c. with rhIL-7-hyFc (1.25 mg kg −1 ). Three days after rhIL-7-hyFc treatment, mice were treated i.v. with PD-L1×CD3 TCE (0.4 μg) 2 times daily. Twenty-four hours after the last treatment, mice were analyzed for TILs ( n = 4–6 per group). (B) Frequencies (left) and numbers (right) of CD8 T, CD4 T reg , CD4 non-T reg , and NK cells. (C) Frequencies of PD-1 − cells (left) and numbers of PD-1 + and PD-1 − cells among the total CD8 T cells (right). (D) Representative plots showing the expression of CD44 and CD62L in PD-1 − CD8 T cells. (E) Frequencies of CD44 + CD62L + (left) and CD44 + CD62L − (right) cells among PD-1 − CD8 T cells. (F, H, and I) Frequencies (left) and numbers (right) of GzmB + cells (F), Prf + cells (H), and Ki-67 + cells (I) among PD-1 − CD8 T cells. (G) Histogram of GzmB expression in PD-1 − CD8 T cells (left) and fold change of GzmB geometric mean fluorescence intensity (gMFI) compared with the buffer group in PD-1 − CD8 T cells. Data are shown as mean ± SEM and summary of two independent experiments (B, C, F, G, and I) or representative of two independent experiments (E and H). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA and Tukey’s multiple comparisons test. ns, not significant. See also <xref ref-type=Figures S7 and . " width="100%" height="100%">

    Journal: Cell Reports Medicine

    Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

    doi: 10.1016/j.xcrm.2024.101567

    Figure Lengend Snippet: TCE combination promotes the cytotoxic activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Experimental scheme. Mice bearing palpable MC38 tumors were injected s.c. with rhIL-7-hyFc (1.25 mg kg −1 ). Three days after rhIL-7-hyFc treatment, mice were treated i.v. with PD-L1×CD3 TCE (0.4 μg) 2 times daily. Twenty-four hours after the last treatment, mice were analyzed for TILs ( n = 4–6 per group). (B) Frequencies (left) and numbers (right) of CD8 T, CD4 T reg , CD4 non-T reg , and NK cells. (C) Frequencies of PD-1 − cells (left) and numbers of PD-1 + and PD-1 − cells among the total CD8 T cells (right). (D) Representative plots showing the expression of CD44 and CD62L in PD-1 − CD8 T cells. (E) Frequencies of CD44 + CD62L + (left) and CD44 + CD62L − (right) cells among PD-1 − CD8 T cells. (F, H, and I) Frequencies (left) and numbers (right) of GzmB + cells (F), Prf + cells (H), and Ki-67 + cells (I) among PD-1 − CD8 T cells. (G) Histogram of GzmB expression in PD-1 − CD8 T cells (left) and fold change of GzmB geometric mean fluorescence intensity (gMFI) compared with the buffer group in PD-1 − CD8 T cells. Data are shown as mean ± SEM and summary of two independent experiments (B, C, F, G, and I) or representative of two independent experiments (E and H). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA and Tukey’s multiple comparisons test. ns, not significant. See also Figures S7 and .

    Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

    Techniques: Activity Assay, Injection, Expressing, Fluorescence

    Transcriptome analysis of CD8 TIL subsets in combination therapy scRNA-seq results of CD8 TILs from mice bearing MC38 tumors treated with rhIL-7-hyFc alone or a combination of rhIL-7-hyFc and TCE. C57BL/6 mice bearing palpable MC38 tumors were injected s.c. with rhIL-7-hyFc (1.25 mg kg −1 ). Three days after rhIL-7-hyFc treatment, mice were treated i.v. with PD-L1×CD3 TCE (0.4 μg) three times daily. Tumors were collected 24 h after the last treatment. Collected tumor tissues were pooled for analysis ( n = 12 rhIL-7-hyFc and n = 24 combination). (A) UMAP plot showing each CD8 TIL cluster. (B) Supervised clustering of CD8 TILs according to gene-expression characteristics (left) and bar graph depicting the proportion of three CD8 TIL subclusters in each treatment condition (right). (C) Heatmap showing the DEGs between supervised groups. (D) Featured plots showing the expression of Pdcd1 (left) and Tcf7 (right) genes. (E) UMAP plot of top six most expanded clones. (F) Number of DEGs in each supervised CD8 TIL subcluster from mice with combination therapy compared with the rhIL-7-hyFc-treated group. (G) Dot plots of GO enrichment analysis of upregulated DEGs by combination therapy in each CD8 TIL subcluster. (H) Violin plots showing the expression of genes related to exhaustion, CM-associated, cytotoxicity, T cell activation, glycolysis, and cell motility. See also <xref ref-type=Figures S9 and ; Table S3 . " width="100%" height="100%">

    Journal: Cell Reports Medicine

    Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

    doi: 10.1016/j.xcrm.2024.101567

    Figure Lengend Snippet: Transcriptome analysis of CD8 TIL subsets in combination therapy scRNA-seq results of CD8 TILs from mice bearing MC38 tumors treated with rhIL-7-hyFc alone or a combination of rhIL-7-hyFc and TCE. C57BL/6 mice bearing palpable MC38 tumors were injected s.c. with rhIL-7-hyFc (1.25 mg kg −1 ). Three days after rhIL-7-hyFc treatment, mice were treated i.v. with PD-L1×CD3 TCE (0.4 μg) three times daily. Tumors were collected 24 h after the last treatment. Collected tumor tissues were pooled for analysis ( n = 12 rhIL-7-hyFc and n = 24 combination). (A) UMAP plot showing each CD8 TIL cluster. (B) Supervised clustering of CD8 TILs according to gene-expression characteristics (left) and bar graph depicting the proportion of three CD8 TIL subclusters in each treatment condition (right). (C) Heatmap showing the DEGs between supervised groups. (D) Featured plots showing the expression of Pdcd1 (left) and Tcf7 (right) genes. (E) UMAP plot of top six most expanded clones. (F) Number of DEGs in each supervised CD8 TIL subcluster from mice with combination therapy compared with the rhIL-7-hyFc-treated group. (G) Dot plots of GO enrichment analysis of upregulated DEGs by combination therapy in each CD8 TIL subcluster. (H) Violin plots showing the expression of genes related to exhaustion, CM-associated, cytotoxicity, T cell activation, glycolysis, and cell motility. See also Figures S9 and ; Table S3 .

    Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

    Techniques: Injection, Gene Expression, Expressing, Clone Assay, Activation Assay

    Journal: Cell Reports Medicine

    Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

    doi: 10.1016/j.xcrm.2024.101567

    Figure Lengend Snippet:

    Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

    Techniques: Purification, Recombinant, Formulation, Flow Cytometry, Amplification, Software, Staining

    Journal: eLife

    Article Title: Meningeal lymphatic drainage promotes T cell responses against Toxoplasma gondii but is dispensable for parasite control in the brain

    doi: 10.7554/eLife.80775

    Figure Lengend Snippet:

    Article Snippet: For samples analyzed using the Gallios flow cytometer, cells were stained for surface markers using the following eBioscience antibodies at 1:200 dilution: CD45-FITC (11-0451-82), CD62L-FITC (11-0621-85), CD80-FITC (11-0801-82), MHC class II (I-A/I-E)-PE (12-5321-82), CD69-PE (12-0691-82), CD11c-PerCP-Cy5.5 (45-0114-82), CD4-PerCP-Cy5.5 (45-0042-82), CD45-PerCP-Cy5.5 (45-0451-82), CD11b-PerCP-Cy5.5 (45-0112-82), CD8α-PerCP-Cy5.5 (45-0081-82), CD45.1-PerCP-Cy5.5 (45-0453-82), CD80-PE-Cy7 (25-0801-82), CD11c-PE-Cy7 (25-0114-82), CD4-PE-Cy7 (25-0041-82), CD8α-PE-Cy7 (25-0081-82), TCR-β-APC (17-5961-82), NK1.1-APC (17-5941-82), CD19-APC (17-0193-82), CD44-AF780 (47-0441-82), CD11b-AF780 (47-0112-82), CD86-EF450 (48-0862-82), MHC class II (I-A/I-E)-EF450 (48-5321-82), CD69-EF450 (48-0691-82), and CD4-EF450 (48-0042-82).

    Techniques: